Bovine Serum Albumin Fraction V, fatty acid free (50g) (BSA-V-100g)

Description

Bovine Serum Albumin Fraction V, fatty acid free
For cell culture applications and fatty acid and lipid research.

This BSA is a single polypeptide chain consisting of about 583 amino acid residues and no carbohydrates.

Free from fatty acids according to current quality control procedures (suitable for lipid research)
Long-term stability
Purity: ≥99 %

[1] R. Salimi, I. Begum, D.M. Varma, B. Nandakrishna, R. Rajesh, S. Vidyasagar, Tenofovir disoproxil fumarate-induced distal renal tubular acidosis: A case report, Int J STD AIDS 31(3) (2020) 276-279.

[2] W.R. Zhang, R. Scherzer, M.M. Estrella, S.B. Ascher, A. Muiru, V. Jotwani, C. Grunfeld, C.R. Parikh, D. Gustafson, S. Kassaye, A. Sharma, M. Cohen, P.C. Tien, D.K. Ng, F.J. Palella, Jr., M.D. Witt, K. Ho, M.G. Shlipak, Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women, AIDS 33(4) (2019) 723-733.

[3] S. Noe, S. Heldwein, H. Jaeger, M. Page, E. Wolf, Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine – results from a German cohort study, Int J STD AIDS 30(5) (2019) 447-452.

[4] M. Lu, H. Dong, D. Bao, B. Liu, H. Liu, Tenofovir disoproxil fumarate induces pheochromocytoma cells apoptosis, Eur J Pharmacol 844 (2019) 139-144.

[5] K. Liu, J. Choi, A. Le, T.C. Yip, V.W. Wong, S.L. Chan, H.L. Chan, M.H. Nguyen, Y.S. Lim, G.L. Wong, Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis, Aliment Pharmacol Ther 50(9) (2019) 1037-1048.

[6] M.J. Keller, L. Wood, J.M. Billingsley, L.L. Ray, J. Goymer, S. Sinclair, A.P. McGinn, M.A. Marzinke, B. Frank, S. Srinivasan, C. Liu, J.M. Atrio, L. Espinoza, N. Mugo, H.M.L. Spiegel, P.L. Anderson, D.N. Fredricks, C.W. Hendrix, J. Marrazzo, S.E. Bosinger, B.C. Herold, Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial, Lancet HIV 6(8) (2019) e498-e508.

[7] S. Kaneko, M. Kurosaki, N. Tamaki, J. Itakura, T. Hayashi, S. Kirino, L. Osawa, K. Watakabe, M. Okada, W. Wang, T. Shimizu, M. Higuchi, K. Takaura, Y. Yasui, K. Tsuchiya, H. Nakanishi, Y. Takahashi, M. Watanabe, N. Izumi, Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate, J Gastroenterol Hepatol 34(11) (2019) 2004-2010.

[8] R. Guner, Z. Kocak Tufan, G.R. Yilmaz, A.T. Mehmet, Tenofovir disoproxil fumarate may not cause renal and bone toxicity in chronic hepatitis B patients: a retrospective cross-sectional study, Turk J Med Sci 49(1) (2019) 451-452.

[9] J.A. Fields, M.K. Swinton, A. Carson, B. Soontornniyomkij, C. Lindsay, M.M. Han, K. Frizzi, S. Sambhwani, A. Murphy, C.L. Achim, R.J. Ellis, N.A. Calcutt, Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice, Sci Rep 9(1) (2019) 17158.

[10] J. Cusato, A. Calcagno, A. De Nicolo, K. Mogyorosi, A. D’Avolio, G. Di Perri, S. Bonora, Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2, Diagn Microbiol Infect Dis 94(2) (2019) 202-204.

[11] A. Calcagno, M. Fiumano, D. Zugna, J. Cusato, C. Montrucchio, L. Marinaro, L. Trentini, M. Ferrara, A. D’Avolio, C. Pizzi, G. Di Perri, S. Bonora, Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?, Pharmacogenomics J 19(1) (2019) 65-71.

[12] P. Zhang, Q. Liu, M. Yuan, L. Wang, Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis, Infect Agent Cancer 13 (2018) 30.

[13] R.R. Patel, R. Presti, L.C. Harrison, W.G. Powderly, P.A. Chan, Tenofovir disoproxil fumarate as pre-exposure prophylaxis for HIV prevention in women with osteoporosis: a case report and review of the literature, Antivir Ther 23(4) (2018) 379-382.